The combination of the BRAF inhibitor vemurafenib and PEG-IFN-α-2b was well tolerated in melanoma patients whose treatment response was correlated with IFNAR1 expression levels (NCT01959633) [340]. The gene discussed is IFNA2; the disease is melanoma.